

Effectiveness of Benzodiazepines Used for Oral Sedation in a Pediatric Dentistry Setting Hemal Patel¹, Christine Chiao¹, Keri Discepolo¹

144 (61.02%)

92 (38.98%)

 7.10 ± 2.10

141 (59.7%)

95 (40.3%)

157 (66.5%)

79 (33.5%)

119 (50.4%)

117 (49.6%)

205 (86.9%)

31 (13.1%)

200 (84.7%)

36 (15.3%)

(P value)

0.05

0.60

0.16

0.29

effectiveness complete

Ability to

treatment

0.11

0.27

0.26

0.67

0.43

(P value)

59.58%

Department of Pediatric Dentistry, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA

Introduction

- •Many studies have been conducted to determine the appropriate dose of oral midazolam in healthy patients. However, sedation in children with behavioral conditions require specialized and individualized clinical management.
- •Some medications such as methylphenidate, amphetamine, and selective serotonin reuptake inhibitors used in the treatment of ADHD/ASD are stimulants and might cancel out the effect of the sedative medications.
- •A review conducted by Vallogini et al.¹, highlighted the need to define appropriate drugs, dosages, sedation level and evaluate patient cooperation in pediatric patients with special needs.
- •The aim of this retrospective study was to examine the effectiveness of oral midazolam combined with nitrous oxide inhalation to sedate pediatric dental patients with behavioral diagnosis (ICD-10 codes F84.0, F90.9, F80.9, F41.9, F32.A, F79) compared with healthy children, age and BMI matched.

Gender

Behavioral condition

Complexity of

Overall behavior

Ability to complete

Overall effectiveness

Assessment factor

procedure

treatment

Gender

BMI %

Age in years

Healthy versus

One tooth versus


Behavioral condition

multiple teeth treated

Results

Behavioral conditions	
ICD-10 codes	Diagnosis
F84.0	Autistic disorder
F90.9	Attention-deficit hyperactivity disorder, unspecified type
F80.9	Developmental disorder of speech and language
F41.9	Anxiety disorder
F32.A	Depression
F79	Intellectual disabilities

Post-treatment Frankl behavior rating



rating 1-2 post-sedation vs. healthy controls (95% CI 1.73-6.56, p = 0.0004)

Healthy

Behavioral diagnosis

Children with behavioral diagnosis had 3.4 times the odds of having Frankl

References

Please click on the link - <u>AAPD</u>

<u>References document</u> or scan

QR code

Patient characteristics, n (%)

Age (years) ± SD

Average BMI %

Behavioral diagnosis

Fair/Poor/Prohibitive

Overall behavior Overall

1 tooth treated

>1 tooth treated

Excellent/Good

Male

Female

Healthy

Effective

Ineffective

(P value)

0.92

0.46

0.51

0.86

0.02

AAPD scan

Study population:

•A retrospective chart review of electronic dental records was conducted of patients at the Franciscan Children's Pediatric Dentistry Clinic between January 1st, 2021 and December 31st, 2022.

Methods

- •Inclusion criteria: 1) Healthy children (ASA I) or children with behavioral diagnosis 2) Ages 3-12 years old 3) Had oral sedation with 0.5 mg/kg midazolam (adjusted for patients with high BMI) for a dental procedure.
- •Effectiveness was evaluated through the following variables: pre- and post-sedation Frankl behavior rating, Houpt behavior rating scale during sedation (overall behavior), ability to complete the treatment and overall effectiveness.

Data analysis:

children with behavior problems⁵.

Total

- •Data was imported in Excel and statistically analyzed in IBM SPSS Statistics 29.0.2.0. Post-sedation Frankl rating in healthy versus children with behavioral conditions was evaluated with Odds ratio.
- •Chi-square was used to evaluate the differences in overall behavior, ability to complete the treatment and overall effectiveness between the two groups.
- Logistic regression was used to analyze the effect of co-variates on the primary outcome.

Discussion

- •0.3 and 0.5 mg/kg midazolam has been found to be safe and effective in providing operative treatment to physically and neurologically compromised pediatric dental patients^{2,3}.
- •This retrospective study allowed comparison between healthy and children with behavioral diagnosis in 3 clinically important aspects overall behavior, ability to complete treatment, and overall effectiveness with no significant differences between the two groups.
- •However, children with behavioral diagnosis showed significantly higher odds of negative behavior during the recovery period. Cortical inhibition and decrease in serotonin concentration may precipitate aggressive behaviors after administration of midazolam. This could be related to the dose of midazolam, severity of the behavioral diagnosis or age. For children undergoing multiple sedation, increasing the dose of midazolam based on the judgment that its effect was insufficient,

may worsen the situation. There may be an increased need of flumazenil in these patients to reduce

- the effect of paradoxical reaction on the children and distress in parents during recovery period⁴.

 •A statistically significant difference was seen in the overall behavior with increase in complexity of the treatment (one tooth versus multiple teeth treated). A retrospective study suggested the use of midazolam be restricted to simple restorations and extractions over a maximum of two visits in
- •Behavior can change intraoperatively with midazolam over the course of the visit. Behavior rating could affect the measure of effectiveness as the ability to complete treatment which often has the clinician completing the treatment even if behavior is a problem intra-operatively.
- •Finally, the small sample size and use of varying concentrations of nitrous oxide, selecting patients who are anxious but not very aggressive and needing minor dental procedures increases the ability to complete treatment in a greater number of patients.